GlassScriptPhysician profile
Mini Santhosh Tharian
NPI 1770086191
$6,262.82
in general payments reported to CMS, 2019-2025
21 companies · $1,086 in 2025
The $1,086 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $472 · 2022: $2,778 · 2023: $885 · 2024: $1,041 · 2025: $1,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,912 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,912.49 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,212.74 | 2022-2025 | Micra, Azure Xt Dr Mri Surescan |
| Astrazeneca Pharmaceuticals LP | $1,200.33 | 2021-2025 | Farxiga, Lokelma, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $719.67 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $691.57 | 2021-2025 | |
| Amgen INC. | $222.34 | 2021-2025 | Repatha, Repatha |
| Abbott Laboratories | $163.40 | 2022-2025 | Cardiomems, Jot Dx |
| Merck Sharp & Dohme LLC | $147.57 | 2022-2025 | Verquvo |
| Pfizer INC. | $147.57 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $138.75 | 2022-2025 | Camzyos |
| Boston Scientific Corporation | $128.00 | 2024 | Watchman Flx |
| Alnylam Pharmaceuticals INC. | $122.88 | 2023 | Amvuttra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $68.21 | 2021-2023 | Lifevest |
| Abiomed | $59.34 | 2024-2025 | Impella |
| Kiniksa Pharmaceuticals International, Plc | $53.57 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $35.85 | 2025 | Assure Wcd |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $34.96 | 2023-2025 | Wegovy |
| Scpharmaceuticals INC. | $33.15 | 2025 | |
| Janssen Pharmaceuticals, INC | $30.62 | 2024 | Xarelto |
| Glaxosmithkline, LLC. | $18.88 | 2025 | Arexvy |
| Bridgebio Pharma, INC. | $17.62 | 2025 | Attruby |
| Kowa Pharmaceuticals America, INC. | $15.80 | 2024 | Livalo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mini Tharian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.